Testing for tumour markers should only be performed if it results in a better patient outcome,
increased quality of life or reduced overall cost of care. Ideally, the clinical value of a tumour …

Tumor markers are playing an increasingly important role in cancer detection and
management. These laboratory-based tests are potentially useful in screening for early …

BACKGROUND The widespread use of prostate‐specific antigen (PSA) screening has had
a tremendous impact on all aspects of the management of prostate carcinoma. Although …

The measurement of tumor markers is currently one of the most rapidly growing areas in
laboratory medicine. Lack of sensitivity and specificity preclude the use of most existing …

Referee: M. Fleisher, Memorial Sloan-Kettering Cancer Center, NY Tumor markers are
molecules that indicate the presence of malignancy. They are potentially useful in cancer …

Purpose: Prostate specific antigen is the most widely used oncological biomarker in
medicine today. Before its implementation as an early diagnostic marker, urologists were …

Prostate-specific antigen (PSA) is the most im-portant serum marker for prostate cancer. It is
increasingly used for screening and early detection, although 65% to 75% of moderately …

Early detection of prostate cancer is problematic, not just because of uncertainly whether a
diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive …

In 1995 the Standing Group on Health Technology Assessment commissioned two
systematic reviews on screening for prostate cancer. The authors of these reports concluded …

Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been
employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved …